GlassScriptPhysician profile
Mauna M Radahd
NPI 1386806743
$1,733.08
in general payments reported to CMS, 2019-2025
24 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $168 · 2021: $161 · 2022: $164 · 2023: $287 · 2024: $319 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.02 | 2021-2025 | |
| Nevro Corp. | $191.66 | 2019-2024 | Senza |
| Globus Medical, INC. | $125.77 | 2025 | Senza |
| Boston Scientific Corporation | $122.44 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $119.08 | 2019 | |
| Medtronic, INC. | $87.53 | 2023 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $74.64 | 2021-2023 | Ztlido |
| Bioventus LLC | $54.02 | 2020-2025 | Durolane |
| Protega Pharmaceutials INC | $52.19 | 2025 | Roxybond |
| Ferring Pharmaceuticals INC. | $48.58 | 2023-2024 | Euflexxa |
| Pacira Pharmaceuticals Incorporated | $48.54 | 2023-2024 | Zilretta, Iovera, Exparel |
| Amgen INC. | $45.09 | 2021-2022 | |
| Johnson & Johnson Health Care Systems INC. | $43.74 | 2022 | |
| Medtronic USA, INC. | $42.00 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.49 | 2024 | Relistor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $26.62 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $25.35 | 2019-2020 | |
| Stryker Corporation | $21.40 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $21.12 | 2025 | |
| Pacira Therapeutics, INC. | $21.10 | 2020 | |
| Grt US Holding, INC. | $20.45 | 2021 | |
| Electronic Waveform Lab, INC. | $20.32 | 2019 | |
| Curonix LLC | $14.59 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Fidia Pharma USA INC. | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauna Radahd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.